ArticleJournal for immunotherapy of cancer2021
Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification.
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma.Discover oncology · 2026Article
- Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study.ImmunoTargets and therapy · 2026Article
- Review
- FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination.Journal of experimental & clinical cancer research : CR · 2025Article
- Review
- CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.Journal of experimental & clinical cancer research : CR · 2025Article
- Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.Current treatment options in oncology · 2025Review
- The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes.Journal of translational medicine · 2025Article
- DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy.Journal of experimental & clinical cancer research : CR · 2025Article
- Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.ACS pharmacology & translational science · 2024Review
- Article
- Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.Current oncology reports · 2023Review
- Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics.Methods and protocols · 2023Article
- Immunotherapy approaches for malignant pleural mesothelioma.Nature reviews. Clinical oncology · 2022Review
- Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations.Cell death & disease · 2022Article
- Review
- Review
- Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma.Journal of clinical medicine · 2021Review
- Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant pleural mesothelioma (MPM) is a rare and aggressive neoplasia affecting the lung mesothelium. Immune checkpoint inhibitors (ICI) in MPM have not been extremely successful, likely due to poor identification of suitable candidate patients for the therapy. We aimed to identify cellular immune fractions associated with clinical outcome and classify patients with MPM based on their immune contexture. For each defined group, we sought for molecular specificities that could help further define our MPM classification at the genomic and transcriptomic level, as well as identify differential therapeutic strategies based on transcriptional signatures predictive of drug response.
methodsThe abundance of 20 immune cell fractions in 516 MPM samples from 7 gene expression datasets was inferred using gene set variation analysis. Identification of clinically relevant fractions was performed with Cox proportional-hazards models adjusted for age, stage, sex, and tumor histology. Immune-based groups were defined based on the identified fractions.
resultsT-helper 2 (T
conclusionsThis study identifies a novel immune-based signature with potential clinical relevance based on T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.